Cargando…
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
Herpes simplex virus (HSV) can be genetically altered to acquire oncolytic properties so that oncolytic HSV (oHSV) preferentially replicates in and kills cancer cells, while sparing normal cells, and inducing anti-tumor immune responses. Over the last three decades, a better understanding of HSV gen...
Autores principales: | Jahan, Nusrat, Ghouse, Shanawaz M., Martuza, Robert L., Rabkin, Samuel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473045/ https://www.ncbi.nlm.nih.gov/pubmed/34578321 http://dx.doi.org/10.3390/v13091740 |
Ejemplares similares
-
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020) -
Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017) -
Immunovirotherapy for glioblastoma
por: Ning, Jianfang, et al.
Publicado: (2014) -
Immunovirotherapy for the treatment of glioblastoma
por: Cheema, Tooba A, et al.
Publicado: (2014) -
Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
por: Monie, Dileep D., et al.
Publicado: (2021)